Search results
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. via Yahoo Finance· 9 hours agoMerck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 2 days agoMerck stock popped Thursday after the Dow Jones stalwart topped Wall Street's first-quarter views on...
Merck shares target raised on strong Q1 performance By Investing.com
Investing.com· 2 days agoOn Thursday, Truist Securities adjusted the stock price target for Merck (NYSE:MRK), a global...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 3 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 2 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $131.25
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock ...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 5 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 2 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
Simply Wall St. via Yahoo Finance· 2 days agoBuffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that...
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patents
Quartz· 2 days agoPharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug...